An investigational live attenuated vaccine led to protection against Salmonella enterica serovar Paratyphi A infection, ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

An Oxford-led study has demonstrated that an oral live-attenuated vaccine, CVD 1902, provided significant protection against S. Paratyphi A infection in healthy adults using a controlled human ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

SAN ANTONIO -- Despite previous concerns, a single infusion of the nonsteroidal anti-inflammatory drug (NSAID) ketorolac alongside standard analgesics was a safe and efficacious pain control option ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

Durham-based Priovant Therapeutics, with Roivant Sciences, has shared encouraging results from its Phase 3 VALOR study evaluating brepocitinib, a potential new treatment for the autoimmune disease ...

GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to an expert endocrine ...